McKinnell: Bextra return likely

Share this article:
Pfizer chief Hank McKinnell told Reuters that the company would likely reintroduce Bextra, "because for many patients it is the best choice or the only choice." McKinnell, speaking in Atlanta at an HIV/AIDS prevention meeting, declined to offer a time frame for the drug's return to market.
Bextra was pulled April 7 at the urging of the FDA, which has questioned the Cox-2 inhibitor's efficacy relative to other painkillers and expressed concern about possible side effects, particularly the skin disease Stevens-Johnson. An FDA spokeswoman told Reuters the agency was "open to discussions" with Pfizer, but reiterated the agency's belief that the risks of the drug outweigh the benefits.
Merck has flirted with the notion of reintroducing Vioxx – most recently last week, when Merck vice president for regulatory affairs Dennis Erb told a congressional committee that the company is in talks with the FDA about a possible Vioxx return. In February, an FDA advisory committee voted 17-15 in favor of allowing Vioxx back on the market. The same panel voted 17-13, with two votes abstaining, to allow a reintroduction of Bextra, and 31-1 to allow Pfizer to continue marketing Celebrex.
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?